United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs... Show more
UTHR broke above its upper Bollinger Band on September 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 39 similar instances where the stock broke above the upper band. In of the 39 cases the stock fell afterwards. This puts the odds of success at .
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UTHR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 49 cases where UTHR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on September 02, 2025. You may want to consider a long position or call options on UTHR as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for UTHR just turned positive on September 02, 2025. Looking at past instances where UTHR's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
UTHR moved above its 50-day moving average on August 05, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for UTHR crossed bullishly above the 50-day moving average on August 13, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where UTHR advanced for three days, in of 315 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 274 cases where UTHR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. UTHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.399) is normal, around the industry mean (16.155). P/E Ratio (14.845) is within average values for comparable stocks, (73.876). Projected Growth (PEG Ratio) (0.734) is also within normal values, averaging (1.880). UTHR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). P/S Ratio (5.988) is also within normal values, averaging (42.667).
a developer of pharmaceutical products
Industry PharmaceuticalsGeneric
A.I.dvisor indicates that over the last year, UTHR has been loosely correlated with MNKD. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if UTHR jumps, then MNKD could also see price increases.
Ticker / NAME | Correlation To UTHR | 1D Price Change % | ||
---|---|---|---|---|
UTHR | 100% | -2.80% | ||
MNKD - UTHR | 38% Loosely correlated | -3.09% | ||
GERN - UTHR | 37% Loosely correlated | -1.43% | ||
DAWN - UTHR | 37% Loosely correlated | -0.94% | ||
ALNY - UTHR | 36% Loosely correlated | +1.37% | ||
CBIO - UTHR | 36% Loosely correlated | +3.48% | ||
More |
Ticker / NAME | Correlation To UTHR | 1D Price Change % |
---|---|---|
UTHR | 100% | -2.80% |
Pharmaceuticals: Generic industry (223 stocks) | 30% Poorly correlated | +0.65% |
Pharmaceuticals industry (387 stocks) | 23% Poorly correlated | +0.55% |